二肽基肽酶-4抑制剂在亚洲射血分数保留的心力衰竭患者中的预后疗效：它们还有机会吗？ - Suppr

Suppr

超能文献

The Prognostic Efficacy of DPP-4 Inhibitors in Asian HFpEF: Do They Still Have a Chance?

作者信息

Chikata Yuichi, Iwata Hiroshi, Minamino Tohru

机构信息

Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

出版信息

JACC Asia. 2023 Jan 3;3(1):105-107. doi: 10.1016/j.jacasi.2022.11.008. eCollection 2023 Feb.

DOI:10.1016/j.jacasi.2022.11.008

PMID:36873754

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9982220/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c863/9982220/017b18b03404/fx1.jpg

相似文献

The Prognostic Efficacy of DPP-4 Inhibitors in Asian HFpEF: Do They Still Have a Chance?二肽基肽酶-4抑制剂在亚洲射血分数保留的心力衰竭患者中的预后疗效：它们还有机会吗？

JACC Asia. 2023 Jan 3;3(1):105-107. doi: 10.1016/j.jacasi.2022.11.008. eCollection 2023 Feb.

Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes.二肽基肽酶-4抑制剂对射血分数保留的心力衰竭合并糖尿病的有益作用。

JACC Asia. 2023 Jan 3;3(1):93-104. doi: 10.1016/j.jacasi.2022.09.015. eCollection 2023 Feb.

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure　- Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry.二肽基肽酶-4 抑制剂对糖尿病合并心力衰竭患者心血管结局和心功能的影响——来自茨城县心脏评估研究-心力衰竭（ICAS-HF）登记的见解。

Circ J. 2017 Oct 25;81(11):1662-1669. doi: 10.1253/circj.CJ-17-0240. Epub 2017 Jun 6.

Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis.二肽基肽酶-4抑制剂对亚洲和高加索2型糖尿病患者的疗效及对β细胞功能的影响：一项荟萃分析。

J Diabetes. 2015 May;7(3):347-59. doi: 10.1111/1753-0407.12196. Epub 2014 Sep 10.

Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus.二肽基肽酶-4 抑制剂在心力衰竭合并糖尿病患者中的再评价。

Diabetes Res Clin Pract. 2023 Aug;202:110798. doi: 10.1016/j.diabres.2023.110798. Epub 2023 Jun 24.

A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats.二肽基肽酶-4 抑制剂可改善 Dahl 盐敏感性大鼠的舒张功能障碍。

J Mol Cell Cardiol. 2019 Apr;129:257-265. doi: 10.1016/j.yjmcc.2019.03.009. Epub 2019 Mar 14.

Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes.二肽基肽酶-4 抑制剂与亚洲糖尿病患者过敏性鼻炎的相关性。

Int J Environ Res Public Health. 2019 Apr 12;16(8):1323. doi: 10.3390/ijerph16081323.

Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan.二肽基肽酶 4 抑制剂可降低慢性丙型肝炎感染合并 2 型糖尿病患者发生肝细胞癌的风险：来自中国台湾的一项全国性研究。

Front Public Health. 2021 Sep 17;9:711723. doi: 10.3389/fpubh.2021.711723. eCollection 2021.

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Kidney Transplant Recipients with Post-transplant Diabetes Mellitus (PTDM)- a Systematic Review and Meta-Analysis.二肽基肽酶-4抑制剂在肾移植后糖尿病（PTDM）受者中的疗效和安全性——一项系统评价与荟萃分析

Curr Diabetes Rev. 2020;16(6):580-585. doi: 10.2174/1573399815666190321144310.

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.二肽基肽酶-4 在肾脏疾病中的作用：以利格列汀为例聚焦二肽基肽酶-4 抑制剂的肾脏作用。

Clin Sci (Lond). 2018 Feb 28;132(4):489-507. doi: 10.1042/CS20180031.

本文引用的文献

JACC Asia. 2023 Jan 3;3(1):93-104. doi: 10.1016/j.jacasi.2022.09.015. eCollection 2023 Feb.

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.恩格列净治疗伴有或不伴有糖尿病的射血分数保留的心力衰竭。

Circulation. 2022 Aug 30;146(9):676-686. doi: 10.1161/CIRCULATIONAHA.122.059785. Epub 2022 Jun 28.

Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis.二肽基肽酶-4 抑制剂通过胰岛素样生长因子-1 轴降低经皮冠状动脉介入治疗后糖尿病患者的长期心血管风险。

Sci Rep. 2022 Mar 24;12(1):5129. doi: 10.1038/s41598-022-09059-2.

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.二肽基肽酶-4 抑制剂、胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂对心肾结局的影响：23 项心血管结局试验的网络荟萃分析。

Cardiovasc Diabetol. 2022 Mar 16;21(1):42. doi: 10.1186/s12933-022-01474-z.

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。

N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.

DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway.二肽基肽酶-4抑制剂通过胰高血糖素样肽-1依赖性抑制烟酰胺腺嘌呤二核苷酸磷酸氧化酶4-组蛋白去乙酰化酶4信号通路减轻血管紧张素II诱导的心肌肥大。

Hypertension. 2020 Apr;75(4):991-1001. doi: 10.1161/HYPERTENSIONAHA.119.14400. Epub 2020 Mar 11.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.利拉利汀对比安慰剂对伴有高心血管和肾脏风险的 2 型糖尿病成人患者主要心血管事件的影响：CARMELINA 随机临床试验。

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry.心力衰竭住院患者中与糖尿病相关的时间趋势和因素：来自“遵循指南-心力衰竭”注册研究的结果

Am Heart J. 2016 Dec;182:9-20. doi: 10.1016/j.ahj.2016.07.025. Epub 2016 Aug 27.

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.二肽基肽酶-4抑制剂与2型糖尿病患者的心力衰竭风险：随机和观察性研究的系统评价与荟萃分析

BMJ. 2016 Feb 17;352:i610. doi: 10.1136/bmj.i610.

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.二肽基肽酶-4 抑制剂与心力衰竭：一项随机临床试验的荟萃分析。

Nutr Metab Cardiovasc Dis. 2014 Jul;24(7):689-97. doi: 10.1016/j.numecd.2014.01.017. Epub 2014 Mar 5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验